The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Enhanced half‐life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.

[1]  E. Santagostino,et al.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. , 2016, Blood.

[2]  E. Santagostino,et al.  First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a , 2015 .

[3]  M. Ezban,et al.  Factor IX‐deficient plasma spiked with N9‐GP behaves similarly to N9‐GP post‐administration clinical samples in N9‐GP ELISA and FIX activity assays , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[5]  J. Dodt,et al.  Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  A. Tiede,et al.  Half‐life extended factor VIII for the treatment of hemophilia A , 2015, Journal of thrombosis and haemostasis : JTH.

[7]  P. Collins,et al.  Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia , 2015, British journal of haematology.

[8]  J. Mahlangu,et al.  Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A , 2015, Journal of thrombosis and haemostasis : JTH.

[9]  E. Santagostino,et al.  Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  E. Neufeld,et al.  Transition considerations for extended half‐life factor products , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  M. Carcao.  Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit? , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[13]  C. Hermans,et al.  Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study , 2015, British journal of haematology.

[14]  M. Ozelo,et al.  Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates , 2015, British journal of haematology.

[15]  A. Aouba,et al.  Batch recall of French plasma‐derived products due to variant Creutzfeldt‐Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[17]  L. Boggio,et al.  Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study , 2014 .

[18]  J. Sommer,et al.  Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity , 2014, Thrombosis and Haemostasis.

[19]  V. Laux,et al.  Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[21]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[22]  B. Konkle,et al.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[24]  T. Weimer,et al.  Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin , 2013, Thrombosis and Haemostasis.

[25]  J. Dodt,et al.  Recommendations on the potency labelling of factor VIII and factor IX concentrates , 2013, Journal of thrombosis and haemostasis : JTH.

[26]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[27]  L. Thim,et al.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. , 2013, Blood.

[28]  P. Collins,et al.  Measurement of factor VIII pharmacokinetics in routine clinical practice , 2013, Journal of thrombosis and haemostasis : JTH.

[29]  R. Liesner,et al.  Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) , 2013, British journal of haematology.

[30]  A. Bitonti,et al.  Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein , 2013, Journal of thrombosis and haemostasis : JTH.

[31]  J. Stockman.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom , 2013 .

[32]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[33]  S. Pipe.  The hope and reality of long‐acting hemophilia products , 2012, American journal of hematology.

[34]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[35]  A. Bitonti,et al.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. , 2012, Blood.

[36]  H. Ehrlich,et al.  BAX 855, a PEGylated rFVIII product with prolonged half-life , 2011, Hämostaseologie.

[37]  P. Giangrande,et al.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. , 2011, Blood.

[38]  T. Nichols,et al.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. , 2011, Blood.

[39]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  John E. Murphy,et al.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. , 2010, Blood.

[41]  R. Liesner,et al.  A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A , 2010, British journal of haematology.

[42]  A. Bitonti,et al.  Prolonged activity of factor IX as a monomeric Fc fusion protein. , 2010, Blood.

[43]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.